PeyriereH, CociglioM, MargueritteG, VallatC, BlayacJ-P, Hillaire-BuysD.Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother2004;38:422–7. Epub 23 Jan 2004. DOI 10.1345/aphl.D237
2.
DalleJH, AuvrignonA, VassalG, LevergerG, KalifaC.Methotrexate–ciprofloxacin interaction: report of two cases of severe intoxication. Arch Pediatr2001;8:1078–81.
3.
NaranjoCA, BustoU, SellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
4.
WardA, ChaffmanMO, SorkinEM. Dantrolene: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs1986;32:130–68.
5.
WuisEW, JanssenMG, VreeTB, van der KleijnE.Determination of a dantrolene metabolite, 5-(p-nitrophenyl)-2-furoic acid, in plasma and urine by high-performance liquid chromatography. J Chromatogr1990;526:575–80.
6.
LermanJ, McLeodME, StrongHA. Pharmacokinetics of intravenous dantrolene in children. Anesthesiology1989;70:625–9.
7.
VallnerJJ, SternsonLA, ParsonsDL. Interaction of dantrolene sodium with human serum albumin. J Pharm Sci1976;65:873–7.
